



Viral Epidemiology Snapshot: February 20-26, 2022

Prepared by Anne Hall, Ph.D., M(ASCP) on behalf of the Molecular Diagnostics/Virology Labs

CoV-2, Flu, & RSV

Virus	#Tested	#Positive	% Positive
Flu A	427	31	7.3%
Flu B	427	1	0.2%
RSV	296	2	0.7%
CoV-2 PUI	1105	44	4.0%
CoV-2 Surveillance	437	3	0.7%


Other Respiratory Viruses

Virus	#Tested	#Positive	% Positive
Adenovirus	295	24	8.1%
Coronavirus 229E	295	3	1.0%
Coronavirus HKU1	295	0	0.0%
Coronavirus NL63	295	1	0.3%
Coronavirus OC43	295	23	7.8%
Metapneumovirus	295	22	7.5%
Rhinovirus/Enterovirus	295	95	32.2%
Parainfluenza 1	295	0	0.0%
Parainfluenza 2	295	0	0.0%
Parainfluenza 3	295	2	0.7%
Parainfluenza 4	295	1	0.3%

Flu A Subtyping

2009 H1N1	0
Seasonal H1	0
Seasonal H3	6
No Subtype	25
Pending subtype	0

Flu, RSV, & CoV-2 Trends




This report contains results for molecular and antigen tests ordered throughout the CHMCA network and performed at the Akron/Mahoning valley laboratories.

As of 11/14, this report also includes Point-of-Care tests (POCT) for influenza performed at ACHP locations.

Notes on Influenza A subtyping: Influenza A found by the Respiratory Film Array test will also include a subtype. Influenza A found by POCT methods will be listed as "no subtype".

CoV-2 Positivity Rate Trends



Notes on SARS-CoV-2 data: In the top chart, the red CoV-2 line traces the total number of patients testing positive each week. In the bottom chart, the orange line ("PUI") shows data for all patients with symptoms or known exposures ("Patient Under Investigation") while the purple line ("Surv.") shows surveillance data for undergoing pre-procedure screening.

As of 10/31, the surveillance line shows patients who have been designated as "pre-procedure" in their testing order questionnaire, as well as participants in the employee screening program.

